ALVEOFACT® 45 mg/ml 54 mg

DRUG2 trials

Sponsors

Philipps-Universitaet Marburg, Universitaetsklinikum Schleswig-Holstein AöR

Conditions

Idiopathic pulmonary fibrosisRespiratory distress syndrome in preterm infants

Phase 2

Proof-of-principle study of inhaled pulmonary surfactant in patients with Idiopathic Pulmonary Fibrosis (INSURF-IPF)

Not yet recruitingCTIS2023-508544-22-00

Philipps-Universitaet MarburgIdiopathic pulmonary fibrosis

Target: 20Updated: 2025-09-29

Phase 3

A randomised controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (pro.LISA)

RecruitingCTIS2024-516504-42-00

Universitaetsklinikum Schleswig-Holstein AöRRespiratory distress syndrome in preterm infants

Start: 2022-03-05Target: 578Updated: 2025-11-25